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Abstract: Marine sponges belonging to the phylum Porifera (Metazoa), evolutionarily  
the oldest animals are the single best source of marine natural products. The present review 
presents a comprehensive overview of the source, taxonomy, country of origin or geographical 
position, chemical class, and biological activity of sponge-derived new natural products 
discovered between 2001 and 2010. The data has been analyzed with a view to gaining an 
outlook on the future trends and opportunities in the search for new compounds and their 
sources from marine sponges. 
Keywords: marine sponges; porifera; marine natural products; anticancer; sponge-associated 
bacteria; drug; bioactive compounds 
 
1. Introduction 
Discovery of marine derived natural products is a promising, but comparatively new field, which 
started with the discovery of unusual nucleoside derivatives in the sponge Tethya crypta in the 1950s 
by Bergmann and Feeney [1,2]. In the early 1960s, research on marine natural products was driven by 
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chemical studies and few compounds were tested for any relevant bioactivity [3] such as production  
of a pyrrole antibiotic by a marine bacterium Pseudomonas bromoutilis [4]. However, utilization of 
marine organisms as sources of bioactive metabolites started seriously at the end of 1960s [5] with the 
isolation of prostaglandin derivatives from the Caribbean Gorgonian Plexaura homomalla [6]. In the 
1980s effective collaborations were established between marine chemists and pharmacologists and the 
investigations were focused on central nervous system membrane active toxins, ion channel effectors, 
anticancer and anti-viral agents, tumor promoters and anti-inflammatory agents [7]. In the 1990s 
pharmaceutical and biotechnological industries focused their screens on chemical libraries of both natural 
products, as well as synthetic compounds produced by combinatorial methods [8]. Invertebrates, mainly 
sponges, tunicates, bryozoans or molluscs provided the majority of the marine natural products involved 
in clinical or preclinical trials [9]. 
The discovery of marine natural products has accelerated over the last two decades with the  
number of new compounds discovered annually increasing from 20 to more than 200 [10]. It has been 
estimated that by 2010 more than 15,000 new marine natural products (NMNP) had been  
discovered [11–13] with 8368 new compounds recorded for the decade between 2001 and 2010. This 
constitutes over half of all the compounds discovered since 1951. 
Among all the marine organisms investigated, marine sponges (Porifera) are recognized as the 
richest sources of NMNP, with about 4851 compounds to date, contributing to nearly 30% of all 
marine natural products discovered so far. It should be noted that of these, 1499 new compounds were 
isolated in the five years from 2008 to 2012 [14–18]. This makes sponges the most prolific marine 
producers of compounds with more than 200 new compounds reported each year for the last decade [19]. 
With this myriad of NMNP available, numerous studies have revealed a broad spectrum of biological 
activities for these compounds, including anticancer, antiviral, antibacterial, antifungal, antiprotozoal, 
anthelmintic, anti-inflammatory, immunosuppressive, neurosuppressive, neuroprotective, antifouling 
and a range of other bioactivities [20]. In addition, as infectious microorganisms evolve and develop 
resistance to existing pharmaceuticals, marine sponges provide novel leads against bacterial, fungal 
and viral diseases [19,21]. Figure 1a shows the almost linear growth of new compounds over the last 
three decades. It is predicted that if this rate can be sustained, the discovery of marine natural products 
from sponges, in particular, and as well as other major marine organisms will bring about new and 
effective therapies against human diseases [22–24]. 
Figure 1b shows the trends of novel marine natural products discovered from different phyla of 
marine organisms during 2001–2010. The annual discovery of marine natural products remained at  
a constant level of about 500 products in the late 1990s [10] but this number has increased from 600  
to over 1000 compounds from 2008 to 2010, a significant increase which was partly driven by new 
developments in modern analytical technology and instruments, especially the development of the high 
resolution nuclear magnetic resonance spectrometer (NMR) and mass spectrometry (MS) coupled with 
high-performance LC and GC [10]. 
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Figure 1. (a) Number of new compounds isolated from marine organisms per decade  
from 1970 to 2010; (b) Total number of new compounds isolated from different marine 
organisms from 2001 to 2010. 
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Although sponges have shown the highest potential for natural product discovery, no comprehensive 
reviews have been published that focus only on compounds from sponges in terms of their source 
areas, modes of action, chemical class and taxonomy. Two review papers written by Hu et al. 2011 and 
Leal et al. 2012 [10,25] described the overall trends in marine natural products, including  
those from Porifera, during the last two decades. Therefore, we prepared this manuscript based on 
sponge-derived new natural products from 2001 to 2010 and all the graphs and tables generated  
for this paper are based on the data reviewed by Blunt et al. from the Natural Product Reports of 
2003–2012 [13–16,20,26–30]. Information was collected from each individual published paper during 
this time period and data was generated and analyzed accordingly. 
Sponges are exclusively aquatic animals that dominate in many benthic habitats. They are sessile and 
do not have tissues or sensory organs but have different types of cells which conduct all forms of bodily 
function. They consume food and excrete waste products within cells without a body cavity [31]. 
Numerous ecological studies have shown that secondary metabolites produced by sponges often 
serve defensive purposes to protect them from threats such as predator attacks, microbial infections, 
biofouling, and overgrowth by other sessile organisms [32,33]. For this reason Porifera are attractive 
subjects for natural product chemists due to the sheer number of metabolites produced, the novelty of 
structure encountered, and the therapeutic potential of these compounds in the treatment of human 
diseases [7]. There is evidence that some compounds originally found in sponge cells are synthesized 
by microorganisms associated with sponges, since the mesohyl of sponges is often inhabited by microbes 
and many poriferan natural products resemble metabolites produced by marine microbes [34]. 
However, these natural products have interesting biomedical potential, pharmaceutical relevance 
and diverse biotechnological applications [5,35–39]. Moreover, sponge-derived antifouling molecules 
have been found to be less toxic, environmentally friendly biocides that are often very effective [40]. 
It is of both scientific and industrial interest as to why and how marine sponges possess such a  
high diversity of novel marine natural products. As the oldest metazoan, sponges have survived in  
the ocean for over 600 million years [41] throughout the vast changes experienced by the ocean.  
The fact that sponges still exist in all waters from fresh to saline, from intertidal to deep-sea, from 
tropical to frozen waters indicates the tremendous ability of sponges to respond and adapt to the  
varied environmental conditions over this period. In addition, sponges are one of the most efficient 
sessile filter feeders: they can filter up to 24 m
3
·kg
−1
 day
−1
 [42]. Bacterial numbers in sponge tissue 
often exceed those of the surrounding seawater by two to three orders of magnitude as the sponge 
mesohyl provides a unique ecological niche for particular bacterial species. In many cases, sponge 
mesohyl harbours the bacterial symbionts (30%–60%) [43]. Bacteria provide their hosts with products 
of their metabolism, thereby granting the sponge access to bacteria-specific traits such as autotrophy, 
nitrogen fixation and nitrification [44]. Other examples show that sponge-associated bacteria can 
process metabolic waste compounds, stabilize the sponge skeleton and provide protection against UV 
radiation [35,45,46]. The most prominent example of sponge bacterial symbiosis, however, is the 
involvement of bacteria in the production of bioactive metabolites [47] that have a role in defense [48]. 
These highly intensive, constant interactions with the environment have given sponges a unique 
biochemistry to produce the high diversity of metabolites that can either help them survive or prompt 
them to evolve. Being attached to a solid surface, a sponge is unable to escape when confronted with  
a predator, and so, when threatened they release stored secondary metabolites that have cytotoxic, 
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antibiotic and feeding deterrent properties [48]. Some chemicals prevent settlement of fouling organisms 
on the sponge surface and restrict competition for space with neighbors. The sponge bacterial associations 
and interactions have been widely studied, with evidence that the sponge-associated bacteria can  
help the sponges to produce secondary metabolites to protect them against their predators [49]. In an 
ecological context, sponges have developed special mechanisms to protect themselves from pathogenic 
bacteria, viruses, parasites, fungus and other predators that include both chemical defense mechanisms 
and physiological responses. Chemical defense mechanisms help to protect sponges against certain 
deleterious bacteria [33,50,51]. In this way, sponges provide novel leads against viral, fungal and parasitic 
diseases [52]. By producing different types of toxins or malevolent tastes and odors, sponges protect 
themselves against predators or inhibit coral overgrowth that could threaten the sponge osculum or 
other systems. As a physical defense they have spicules and collagen. Sponges may also succumb to 
microbial and fungal infections which could result in the disintegration of the sponge fibers/tissue  
and ultimately lead to sponge death [53]. The fact that sponges are susceptible to microbial infection 
suggests that they should also possess mechanisms to prevent these types of diseases [54]. Maldonado 
and co-workers [55] showed how sponges recover from a bacterial infection: their ultrastructural  
study revealed that the sponges secrete successive collagen barriers at the diseased area and abandon 
decaying body parts external to the barrier. 
Recently, the ubiquitous defense enzyme, phospholipase A2 (PLA2) detected in a sponge associated 
bacterium envisaged the possible functional role in the ecological succession of the host sponge 
against predatory/fouling pressure in the habitat [56]. In response to predators and pathogens, sponges 
have engineered complex secondary metabolites from a diverse set of biological precursors. Secondary 
metabolites are organic compounds that are not directly involved in the normal growth, development 
or reproduction of organisms. These metabolites produced by sponges and their associated microflora 
can be classified chemically as alkaloids, terpenoids, glycosides, phenols, phenazines, polyketides, fatty 
acid products and peptides, amino acid analogues, nucleosides, porphyrins, aliphatic cyclic peroxides 
and sterols [57,58]. Many of these compounds are very potent because the diluting effect of the ocean 
drives the construction of molecules that are highly active and stable in saline conditions [59]. 
Given the significance of sponges in marine natural product discovery, the aim of this review is to 
present a comprehensive overview of sponge-derived natural product discovery during the recent 
decade from 2001 to 2010, in order to understand the defining trends and provide insights into avenues 
for further compound discovery. The temporal trends of the discovery of sponge-derived marine 
natural products and their biological activities, the sources of discovery in terms of sponge taxonomy, 
the chemical classes of these natural products, and the countries of collection have been categorized. 
Our analysis also includes a short description of the relative distribution and contribution of these 
discoveries with reference to governmental funding, policies and known national priorities given to 
marine natural products. Finally, the opportunities and challenges have been identified for future  
R and D in this fast growing field. 
The new compounds isolated during the last decade were classified into 18 chemical classes including 
acid, alkaloid, ester, fatty acid, glycoside, ketone, lipid, macrolide, alcohol, peptide, peroxide, polyketide, 
quinone, steroid, sterol, terpene, terpenoid and unclassified, based on the data reviewed by Blunt et al. 
from Natural Product Reports of 2003 to 2012 [13–16,20,26–30]. The World Porifera Database [60]  
was used for the taxonomic classification of the sponges mentioned in the Natural Product  
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Reports [13–16,20,26–30]. The World Register of Marine Species (WoRMS) database [60] was also 
used to cross check detailed taxonomical information (order and family) for each surveyed species and to 
validate and/or update their scientific names [61]. 
During the recent decade the sponges collected were from 19 known orders as well as 12 sponges  
of unknown identity which provided new compounds. These included Agelasida, Astrophorida, 
Axinellida, Chondrosida, Choristida, Clathrinida, Dendroceratida, Dictyoceratida, Hadromerida, 
Halichondrida, Haplosclerida, Homosclerophorida, Leucosolenida, Lithistida, Lyssacinosida, 
Ocilosclerida, Poecilosclerida, Spirophorida and Verongida. Sixty two countries (with Antarctica 
labeled as a country for reporting purposes) were the sources for the sponge samples studied. The 
bioactivities were mainly classified as anti-Alzheimer’s, antibacterial, antituberculosis, anticancer, 
antifungal, anti-inflammatory, antimalarial, antiviral and anti-HIV. 
2. New Compounds and Their Distribution 2001–2010 
2.1. Yearly Distribution of Phyla that Produce Natural Products Discovered from 2001 to 2010 
To investigate the distribution of sources of NMNP, 12 different categories including a separate 
group comprising marine microorganisms and phytoplankton were used for this review (Figure 2). 
Invertebrates comprise approximately 60% of all marine animal diversity [62]. Most belong to the phyla 
Porifera (sponges), Annelida, Arthropoda, Bryozoa, Cnidaria, Echinodermata, Mollusca and Chordata. 
Several studies addressing marine invertebrates also include these groups of organisms [32,33,63]. 
Figure 2. Total number of new compounds isolated from different types of marine  
sources, 2001–2010. 
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As highlighted in other reviews [10,64], the phyla Porifera and Cnidaria have been the two main 
sources of NMNP. During the last 10 years from 2001 to 2010, more than 2400 new natural products 
have been discovered from 542 genera and 671 species of sponges. These sponges belong to 19 known 
orders and 74 families, contributing about 29% of the marine natural products discovered during this 
decade, making it the largest source among all marine organisms [48,65]. 
2.2. Sponges (Porifera) as a Source of New Natural Products and Drugs for the Future 
A review in 2003 collected the most important marine natural compounds which were undergoing 
preclinical and clinical trials (I, II, III) for anticancer activity. Among those, compounds from  
sponges were the following: Discodermolide, Hemiasterlins A & B, modified Halichondrin B,  
KRN-7000, Alipkinidine (alkaloid), Fascaphysins (alkaloid), Isohomohalichondrin B, Halichondrin B, 
Laulimalide/Fijianolide, 5-Methoxyamphimedine (alkaloid) and Variolin (alkaloid) [66]. A review paper 
was published by Sipkema et al. 2004 about the drugs from marine sponges [67]. 
Marine natural sources as potential anticancer agents were reviewed in 2011 which mentioned  
39 marine-derived potential anticancer agents and among them 18 compounds from sponges with 
different mechanisms of action [68]. Interestingly, from the 16 marine natural products that are currently 
under preclinical trials as new drug candidates, most are derived from invertebrates. Of these, Porifera 
remain the most important phylum, with six of the 16 compounds [69–71]. A review paper published  
in 2013 classified anticancer molecules according to their current status in the clinical phase trials 
(approved/phase IV/phase III/phase II/phase I) and updated the data to April 2012 [72]. A very recent 
review, published in 2014, showed the compounds derived from marine sources currently in clinical 
trials against cancer with more updated information on clinical and late preclinical developments [73]. 
This paper also mentioned that although many compounds showed potential against cancer and entered 
clinical trials in cancer, to date, only Cytarabine, Yondelis
®
 (ET743), Eribulin (a synthetic derivative 
based on the structure of Halichondrin B), and the Dolastatin 10 derivative, monomethylauristatin E 
(MMAE or vedotin) as a warhead, have been approved for use in humans (Adcetris
®
) [73]. 
Although a number of compounds from sponges showed promising activity to be potential drug 
candidates over the last few decades they are generally not ready for further development due to the 
challenge of obtaining continuous and larger supplies of the compounds, unless they can be chemically 
synthesized. Considerable quantities of a drug candidate are vital for clinical trials, but only a few 
milligrams of most natural products can be isolated from marine samples [74]. One solution is farming 
sponges to source bioactive metabolites [75]. On the other hand, sponge compounds that are produced 
by sponge-associated microorganisms can be scaled up as the microorganisms are able to flourish 
independently of the sponge. Another way to ensure supply is using sponge cell culture, although this 
is still a growing area. Muller et al. in 2000 described the production of bioactive compounds by 
sponge cell culture [76] and Zhang et al. in 2003 and Cao et al. in 2007 showed improved cell 
proliferation and spiculogenesis from primmorphs of sponges and dynamics of spicule production in  
in vitro sponge cell culture systems [77]. The sustainable production of bioactive compounds from 
sponges was reviewed in 2004 [78] and again in 2009 where the advantage and disadvantage of sponge 
cell culture was discussed, with the conclusion that the understanding of the metabolic pathways is one 
of the potential advantages of sponge cell culture systems [79]. However, the most promising solution was 
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answered by Wilson et al. in 2014; his findings illuminated two promising approaches for addressing 
the supply problem [80]: firstly, large-scale cultivation of the microorganisms that produce interesting 
metabolites, and secondly, expressing the biosynthetic pathway of interest in an easily cultivable 
surrogate host. The discovery of Wilson and Piel and their colleagues identified Entotheonella and 
members of the newly proposed phylum Tectomicrobia as a ―biochemically talented‖ phylum on a par 
with the actinomycetes [80–82]. Thus, these results could facilitate a new era of drug discovery. 
2.3. The Distribution of New Marine Natural Products from Sponges 
To date, about 11,000 species of sponges have been formally described of which approximately 
8500 are considered valid, but as many as twice those numbers are thought to exist [83]. Well known 
sponge fauna in the Caribbean, Mediterranean, and the British Isles each contain 500–800 species, 
whereas less well characterized sponge fauna in Australia, Papua New Guinea and Indonesia possess a 
high biodiversity [84]. Sponges are currently divided into four distinct classes, 25 orders, 128 families 
and 680 genera [59,60]. 
The sponges reported to produce new compounds in the last ten years were from 19 known orders 
although a number of sponges were not identified. A careful analysis of the trends of the discovery  
of new bioactive compounds from different orders of sponges is presented here to guide scientists in 
future discoveries. 
As shown in Figure 3a, 504, 355, 337, 274 and 201 new compounds were found from the five orders 
Dictyoceratida, Haplosclerida, Poecilosclerida, Halichondrida and Astrophorida, respectively. Notably, 
these five orders contributed more than 70% of the new compounds. The highest numbers of new 
compounds were found from Dictyoceratida with 72 found in 2008, 66 in 2004, 63 in 2009, 58 in 2001 
and 51 in 2005. 
Table 1 shows that some orders have been found to be productive sources of NMNP, many with a 
large chemical diversity. Astrophorida, Dictyoceratida, Halichondrida, Haplosclerida and Poecilosclerida 
are the orders from which more than 50 species were studied [83]. 
Dictyoceratida contributed at least 16% of new compounds each year except in 2010 (11.9%), 
reaching a peak of 28.5% in 2005 (Figure 3b). Haplosclerida contributed at least 13.58% of new 
compounds each year except 2004 and 2008 with values of 9.4% and 7.7% respectively. This order yielded 
the highest number of compounds in 2001 at 24.6%. In the case of Poecilosclerida, a gradual increase 
was observed until 2004 and reached a peak in 2009 at 22.1%. From 2004 to 2008 Halichondrida 
contributed at least 11.4% new compounds each year. 
This corresponds with a recent review on clinically active compounds from sponges which had 
Astrophorida, Chondrosida, Dendroceratida, Dictyoceratida, Hadromerida, Halichondrida, Haplosclerida, 
Lithistida, Poecilosclerida, Spirophorida and Verongida as the main orders from which clinically 
active compounds were found [85]. Leal et al. 2012, covering 1990–2009, found that NMNP were 
recorded in 17 orders of Demospongiae, and about 89% of the natural products were derived from  
only eight of those orders, namely Astrophorida, Dictyoceratida, Halichondrida, Haplosclerida, 
Homosclerophorida, Lithistida, Poecilosclerida and Verongida [25]. 
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Figure 3. (a) Total number of new compounds isolated from different orders of marine 
sponges 2001–2010; (b) Distribution of new compounds isolated from different orders of 
marine sponges as a percentage found within the year, 2001–2010. 
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Table 1. Total number of new compounds isolated from different orders of marine  
sponges with number of families, genera, species and number of references published from 
2001 to 2010. 
Order Number of Families Number of Genera Number of Species Number of References 
Agelasida 9 9 21 24 
Astrophorida 26 58 63 62 
Axinellida 2 2 2 2 
Chondrosida 1 1 1 1 
Choristida 3 3 3 3 
Clathrinida 5 5 7 7 
Dendroceratida 7 10 11 13 
Dictyoceratida 40 117 145 161 
Hadromerida 24 31 32 33 
Halichondrida 31 69 86 84 
Haplosclerida 52 80 100 120 
Homosclerophorida 10 20 39 50 
Leucosolenida 1 1 1 1 
Lithistida 14 20 23 32 
Lyssacinosida 2 2 2 2 
Ocilosclerida 1 1 1 2 
Poecilosclerida 67 68 81 83 
Spirophorida 4 4 4 5 
Unknown 8 12 12 10 
Verongida 27 29 37 46 
Total 334 542 671 741 
All NMNP discovered since 1990 were recorded in 64 families belonging to the phylum Porifera. 
However, about 51% of these products were derived from only nine families: Spongiidae, Dysideidae  
and Thorectidae in the order Dictyoceratida; Chalinidae and Petrosiidae in the order Haplosclerida; 
Halichondriidae in the order Halichondrida; Ancorinidae belonging to the order Astrophorida; 
Plakinidae belonging to the order Homosclerophorida and Theonellidae of the order Lithistida. Here, 
the highest increase in the number of NMNP annually discovered was recorded for the families Chalinidae 
and Spongiidae. The family Theonellidae has yielded a number of unique compounds [86] with a broad 
spectrum of biological activities, including antifungal [87] and cancer cell growth inhibitors [88,89]. 
Figure 4 shows that between 9 and 16 genera were found to produce new molecules each year  
from the order Dictyoceratida which revealed a high availability of different genera from this 
particular order, with the highest number found in 2009. This order will be examined in greater detail  
in a subsequent review covering 2001–2010. Genera belonging to the orders Haplosclerida, 
Halichondrida, Poecilosclerida, and Astrophorida also showed more than five productive genera for 
most of the last decade. The number of new compounds correlated with the high diversity of sponges 
because the higher the diversity the higher the possibility of getting more novel compounds. Another 
possible reason that makes Dictyoceratida the most prolific producers of NMNP as well as 
Astrophorida, Haplosclerida, Homosclerophorida and Halichondrida is because these orders harbor 
high densities of microorganisms [25,85]. 
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Figure 4. Number of different types of genera used for isolation of new compounds from 
different orders of marine sponges from 2001 to 2010. 
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antifouling compounds [39]. Whilst the microbes associated with the sponges produce the secondary 
metabolites, possibly all of these sponges have particular microbial associations [99]. More research is 
necessary to explore the relationship between microorganisms and phytoplankton associated with 
sponges because it has been suggested that (at least) some of the bioactive secondary metabolites 
isolated from sponges are produced by functional enzyme clusters which originated from these 
microorganisms. The role of these microorganisms in sponge biology varies from source of nutrition to 
mutualistic symbiosis with the sponge [100]. 
It has been recognized that metabolites synthesized by marine microorganisms associated with 
sponges could become a major source for the discovery of new drugs, not only because the biological 
diversity in marine ecosystems like coral reefs or deep sea floors is probably higher than in the 
rainforest, but because marine microorganisms offer a renewable resource for the scale-up and 
development of potentially new drugs [101,102]. 
A number of examples of the functions of the sponge-associated microorganisms are provided to 
signify the diversity of functions. Dudler and Eberl 2006 conducted a study on interactions between 
bacteria and eukaryotes which showed increasing evidence to support the hypothesis that secondary 
metabolites produced by symbiotic bacteria are a result of bacterial cell-to-cell signaling [103].  
In a similar vein, Schmidt et al. 2008 looked at how organisms cooperate in the synthesis of natural 
products. They found that partners may exchange and modify the natural products produced by each 
other and also explained how these secondary metabolites are utilized by the host organisms [104]. 
Many sponge-derived metabolites resemble bacterial natural products or belong to substance classes 
typical for these microorganisms [82]. In a recent paper, the Piel group demonstrated beyond doubt 
that almost all bioactive polyketides and peptides known from the marine sponge Theonella swinhoei 
were attributed to a single phylotype, Entotheonella spp. and are extensively distributed in sponges [80]. 
The diversity in the locations (Okinawa, the Philippines, Indonesia, the Red Sea, Italy, South Africa, 
and Papua New Guinea) and genera of sponges (Amphimedon sp. and Acanthostrongylophora) responsible 
for the production of manzamine alkaloids are widely believed to be a result of a symbiotic relationship 
between these sponges with common or closely related microorganism(s), which may account for the 
generation of manzamine enantiomers [105]. 
Crambe crambe (Schmidt, 1862) (Poecilosclerida) is a red incrusting marine sponge present in the 
Mediterranean Sea and reported to produce diverse PGAs, namely crambescidins 800, 816, 830, 844, 
as well as isocrambescidin [106,107]. Using 16S rRNA gene pyrosequencing it has been found that the 
associated bacterial community of C. crambe is dominated by a single bacterial species affiliated to the 
Betaproteobacteria [108]. 
2.6. The Distribution of Chemical Classes 
Although acid, ester, ketone, peroxide do not directly fall into chemical classes, we considered these 
as chemical classes just to show the distribution as such described in the original paper as well as 
mentioned by Blunt et al. [13–16,20,26–30] in their annual review of marine natural products that 
were used in preparing this manuscript. In fact, classes of natural products should be classified based 
on their biosynthesis. However, it is important to remember that a macrolide is often a polyketide and a 
sterol a steroid and fatty acid belongs to lipid. 
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A wide range of chemical and functional diversity has been observed among new compounds 
during the last decade. The analyzed data (Figure 5a) has shown that in the last ten years 450, 331, 188 
and 155 new compounds were classified as alkaloids, terpenes, terpenoids and peptides, respectively, 
and these four classes make up approximately 50% of compounds discovered. While alkaloids 
contributed 20% of the new molecules the terpene/terpenoid classification which are often not readily 
distinguishable, together made up 23% of the total within the decade. 
Figure 5. (a) Chemical classes of new compounds isolated from marine sponges from 
2001 to 2010; (b) The distribution of different chemical classes of new compounds isolated 
from marine sponges from 2001 to 2010. 
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alkaloids, terpenes, terpenoids, trichoverroids and prodigiosin derivatives, diglucosyl-glycerol, 
polyketides, cyclopeptides, glycoglycerolipid, benzoic acid derivatives are responsible for anticancer 
or antitumor activity; quinolone derivatives for anti HIV activity; fatty acid esters and fatty acids for 
anti-inflammatory activity; alkaloids and quinolone derivatives for antimalarial activity; polyketides 
glycopeptides, α-pyrone derivatives, peptides, proteins, antimycin, lipopeptides, polybrominated 
biphenyl ether, cyclic depsipetide, terpenes, pentaketides, furan carboxylic acid, alkaloid, 
diketopiperazine, anthraquinone, chromones, steroid, lactone, quinolone derivative, trisindole 
derivative, macrolactam, ethers, phenol derivative for antimicrobial activity; and dihydropyridine for 
neuroprotective activity [85]. In this review it was also evident that anticancer, antimicrobial,  
anti-HIV, antiflammatory, antimalarial, and neuroprotective disease and antituberculosis were the main 
classes activity exhibited by most of the new compounds during the recent decade. Terpenoid quinones 
and hydroquinones, the chemical classes found mainly from Dictyoceratid sponges [11,12,20], have 
been continuously reviewed and updated. Sesquiterpenoid quinones and hydroquinones showed 
versatile activities and even a hydro-quinone displays multiple activities [109]. 
The reason that most sponges produce alkaloids could be for protection from predators such as fish 
as alkaloids act as good toxicants against predators. Assman et al. 2000 presented data suggesting  
that bromopyrrole alkaloids fulfill multiple ecological functions in the defense mechanisms of the 
common and diverse genus Agelas [110]. A striking example of the significance of marine alkaloids 
for chemical defense against fish is provided by the red coloured sponge Latrunculia magnificea (order 
Poecilosclerida) from the Red Sea. Even though L. magnificea growth is exposed, it is apparently 
avoided by fish, whereas other sponges from the same habitat that are cryptic are readily consumed by 
fish when artificially exposed [111]. 
Further information on the different classes of secondary metabolites of marine sponges and their 
bioactivities are the subject of previous reviews [14,93,112,113]. 
2.7. The Distribution of Bioactive Compounds 
Table 2 shows that during the decade until 2010, 332, 229, 227, 173 and 149 new bioactive 
compounds were found from Dictyoceratida, Haplosclerida, Poecilosclerida, Halichondrida and 
Astrophorida, respectively, the highest number of new bioactive compounds isolated from different 
orders of sponges in this period. Dictyoceratida alone contributed 20.6% of all bioactives, 
Haplosclerida and Poecilosclerida both contributed 14%, whereas Halichondrida and Astrophorida 
contributed 10.8% and 9.3% respectively. The detail of yearly distribution is presented in Figure 6. 
Therefore, these five orders contributed 69% of bioactive compounds among all the different  
orders of sponges. 
In sponges the role of the chemical constituents is clouded by the complexity of the  
sponge-symbiont relationship [114]. The current body of evidence is too limited to make broad 
generalizations, but it suggests complex chemical and biological interactions that have not yet been 
resolved [115]. This knowledge will feed into strategies to relieve a major bottleneck for sponge 
metabolite production, namely: understanding metabolites production in the sponge [79]. 
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Table 2. Total number of new compounds isolated from different orders of marine sponges with different bioactivities from 2001 to 2010. 
Orders  
of Sponges 
Anti-
Alzheimer’s 
Antibacterial Antituberculosis 
Anticancer/ 
Cytotoxicity 
Antifungal 
Anti-
inflammatory 
Antimalarial 
Anti-
HIV 
Antiviral Miscellaneous Total 
Agelasida 0 17 0 11 6 0 6 0 0 14 54 
Astrophorida 0 8 6 97 7 0 1 5 3 22 149 
Axinellida 0 0 0 0 0 0 0 0 0 8 8 
Chondrosida 0 0 0 3 3 0 0 0 0 0 6 
Choristida 0 0 0 12 0 0 0 0 0 12 24 
Clathrinida 0 4 3 3 2 0 0 0 0 0 12 
Dendroceratida 0 4 0 14 3 3 0 0 0 14 38 
Dictyoceratida 0 38 3 182 11 2 1 5 0 90 332 
Hadromerida 0 2 3 45 1 0 0 5 0 18 74 
Halichondrida 1 18 4 99 16 1 2 1 0 31 173 
Haplosclerida 8 15 2 100 20 0 7 4 0 73 229 
Homosclerophorida 0 2 3 55 10 0 9 1 0 34 114 
Leucosolenida 0 1 0 2 0 0 0 0 0 0 3 
Lithistida 0 5 2 38 9 2 0 16 0 16 88 
Lyssacinosida 0 0 0 1 0 0 0 0 0 0 1 
Ocilosclerida 0 0 0 0 0 0 0 0 0 0 0 
Poecilosclerida 0 17 5 143 21 1 1 4 1 34 227 
Spirophorida 0 0 0 4 0 0 0 0 0 0 4 
Unknown 0 0 0 2 0 0 0 0 0 7 9 
Verongida 0 14 0 17 5 0 0 0 0 34 70 
Total 9 145 31 828 114 9 27 41 4 407 1615 
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The origin and role of a number of compounds such as bioactive peptides within the sponges  
have yet to be clarified, as many of these compounds have potent activities not always clearly related  
to their in situ role [116]. However, it was subsequently found that antimicrobial peptides (AMPs) are 
components of innate immunity, forming the first-line of defense used by any organisms against the 
invading pathogens [117]. Pasupuleti et al. 2012 termed AMPs as the key component of the innate 
immune system [118]. Two good examples of AMPs produced by Porifera are Stylisin and Discodermin 
A [119,120], although many AMPs have been produced since the first production of Discodermin from 
sponges [121]. In 2013 a review paper was published on antimicrobial peptides with versatile biological 
activities which included a few sponges producing AMPs [122]. 
There is a sign that the quick evolution of molecules related to cell adhesion and pathogen killing 
(AMP precursors) has been acute in the successful alteration of sponges [123]. In their 2010 review 
Otero-González et al. discussed the new frontier for microbial infection control by antimicrobial 
peptides including Porifera [121]. A review published by Brogden et al. 2005 commented that translocated 
peptides can modify cytoplasmic membrane septum creation, hinder cell-wall synthesis, constrain 
nucleic-acid synthesis, inhibit protein synthesis, or obstruct enzymatic activity [124]. 
Figure 6. Distribution of bioactive compounds isolated from various marine sponge orders 
2001–2010. 
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carotenoids), electron carriers (ubiquinone, plastoquinone), and mediators of polysaccharide assembly, 
as well as communication and defense mechanisms [125]. Terpenes may also act as safeguard for a 
variety of organisms in the marine world, including algae, sponges, corals, mollusks and fish [33]. 
It is important to note that most of the orders showed cytotoxicity or anticancer activity although 
only a few have been tested for in vivo antitumor activity. In the five year period from 1986 to 1991, 
more than 400 novel marine natural products with cytotoxic activity were reported in the literature [126] 
with the majority of compounds only tested for cytotoxicity in cell culture assays. Although cytotoxic 
activity is regarded as the first indicator in identifying anticancer drugs [127], we have considered 
these compounds to be cytotoxic unless further experimentation indicates their potential role as an 
anticancer drug. Increasing evidence has shown that cell death can be induced via three different 
mechanisms: apoptosis, autophagy and oncosis [128]. Most of these sponge-derived novel compounds 
have been screened for cytotoxic activity but not for apoptosis [129–131], although analysis should 
focus on a number of cancer relevant targets associated with the cell cycle, signal transduction, 
angiogenesis or apoptosis [132–135]. A recent overview (2011) retrieved scientific papers identifying 
39 compounds from marine sponges with apoptosis-inducing anticancer properties [136]. In another 
example that distinguishes cytotoxicity from antitumor activity, a recent study used a novel in vitro 
assay to screen 2036 extracts from 683 individual sponges that led to the identification of bioactive 
compounds (which were prepared in pure form and in sufficient quantities) that could treat solid 
tumors [137]. 
Figure 7a,b show that the number of compounds with reported inhibition of cancer cell lines  
(or cytotoxicity) was highest with the number of 825, antibacterial activity at 145, and antifungal and 
anti-HIV activities at 111 and 41, respectively. Thus, cytotoxicity or anticancer activity contributed at 
least half of the reported activity. Progress towards marine anticancer drugs dominates, with the prime 
source phylum being sponges, followed by microorganisms, tunicates and mollusks [22]. Antiviral and 
anti-HIV activities have been observed from samples of Astrophorida, Lithistida and Poecilosclerida. 
The most promising antiviral substances from sponges appear to be 4-methylaaptamine, manzamines [19], 
besides Papuamides C and D [138], haplosamates A and B [139] and avarol [140] which are examples 
of HIV-inhibiting compounds from different sponges. 
In a recent overview of 132 natural products from marine sources obtained during the period  
2002–2011, which exhibited anti-HIV activity, it was reported that sponges contributed more than half 
of all anti-HIV natural products from marine organisms. These were mainly alkaloids and cyclic 
depsipeptides [141], such as Cortistatin A (CA), a recently discovered natural steroidal alkaloid isolated 
from the marine sponge Corticium simplex [142]. It has been reported to display anti-proliferative 
properties towards human umbilical vein endothelial cells (HUVECs) with an average half-maximal 
inhibitory concentration (IC50) of 0.35 μM [142,143]. A recent study showed that Cortistatin A potently 
suppresses Tat-dependent HIV transcription [144]. Further reading on the structural characteristics  
of sponge derived cyclodepsipeptides can be found in a recent review [145]. It is important to note  
that Halichondrida and Haplosclerida are the only orders from which anti-Alzheimer’s activity was 
reported during the last decade. 
There have been many interesting compounds with unusual structures with potential activity which 
have been observed during the last decade. Some of the compounds are illustrated in Table 3. 
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Figure 7. (a) Total number of new compounds isolated from different marine sponges with 
various bioactivities from 2001 to 2010; (b) The distribution of new compounds isolated 
from different orders of marine sponges with various bioactivities from 2001 to 2010. 
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Table 3. Selected compounds with unusual structure and significant activity from sponges. 
Organism Order Compound Name Chemical Class Special Feature/Activity 
Source, Country, 
Year,/Depth 
Reference 
Sarcotragus sp. Dictyoceratida Sarcotragin A, & B 
Trisnorsesterterpenoid  
lactam 
Showed moderate cytotoxicity  
(LC50 207 μg/mL) toward the leukemia  
cell-line K562 
Seoguipo, Jaeju Island, 
Korea, 2001 
[146] 
Polymastia tenax Hadromerida 
5α,6α-epoxy-24R*-
ethylcholest-8(14)-en-
3β,7α-diol and 5α,6α-
epoxy-24R*-
ethylcholest-8-en-3β, 
7α-diol 
Sterol 
Exhibited significant cytotoxic activity vs. 
human lung carcinoma (A-549), human colon 
carcinomas (HT-29 and H-116), and human 
prostate carcinoma (PC-3) cell lines with the 
LC50 (μg/mL) value of 5–10, 1–5, 1–5, 0.5–1 
and 1–5 
Punta de Betín, Bahía de 
Santa Marta, in the 
Colombian Caribbean, 
Colombia, 2002 
[147] 
Crella spinulata Poecilosclerida Benzylthiocrellidone Bis-dimedone thioether 
First report of a natural product containing a 
dimedone moiety. No activity reported 
Davies and Bowden 
Reefs Australia, 2002 
[148] 
Ectyoplasia ferox  Poecilosclerida Ectyoceramide 
Galactofuranosylceramide 
(GSL) 
The first example of a 
monohexofuranosylceramide and the first 
natural GSL with its first sugar in the 
furanose form. No activity reported 
Island of Rum Cay, 
Bahamas, 2000 
[149] 
Cribrochalina 
olemda 
Haplosclerida Kapakahine E Peptide (cyclic) 
Kapakahine E showed moderate cytotoxicity 
against P388 murine leukemia cells at IC50  
of 5.0 μg/mL 
Pohnpei, Micronesia, 
2003 
[150] 
Haliclona Viscosa Haplosclerida Viscosamine 
Trimeric 3-alkyl 
pyridinium alkaloid 
First trimeric 3-alkyl pyridinium  
compound from a marine environment.  
No activity reported 
Coast of 
Blomstrandhalvøya, 
near Hansneset, 
Kongsfjorden, Arctic 
Ocean, 2003 
[151] 
Phakellia fusca Axinellida Compound 1, 2, 3 5-Fluorouracil alkaloid 
First report of fluorine containing natural 
products from a marine source.  
No activity reported 
Yongxiong Island of the 
Xisha Islands, South 
China Sea, China 2003 
[152] 
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Table 3. Cont. 
Agelas clathrodes Agelasida Clarhamnoside 
Rhamnosylated  
R-Galactosylceramide 
The first Rhamnosylated  
R-Galactosylceramide, a glycolipid  
containing an unusual L-rhamnose unit.  
No activity reported 
Grand Bahamas Island 
(Sweetings Cay), 
Bahamas, 2004 
[153] 
Psammocinia sp. Dictyoceratida Psymberin 
Cytotoxin  
(distantly related to the 
Pederin family) 
Several melanoma, breast, and colon cancer 
cell lines demonstrated high sensitivity  
(LC50 < 2.5 × 10
−9 M) to psymberin,  
and all six leukemia cell lines proved 
comparably insensitive 
Papua New Guinea, 
2004 
[154] 
Callyspongia 
abnormis 
Haploscerida Callynormine A Cyclic Peptide 
Represents a new class of heterodetic cyclic 
peptides (designated endiamino peptides). 
This compound possessing an α-amido-β-
aminoacrylamide cyclization functionality 
Shimoni reef,  
Kenya, 2004 
[155] 
Axinella 
infundibula 
Halichondrida Axinelloside A 
Lipopolysaccharide 
(Sulfated) 
Axinelloside A, a complex polysulfated 
glycolipid, which strongly inhibited the 
activity of human telomerase with an IC50 
value of 0.4 μM  
Shikine-jima Island, the 
Izu Islands, Japan, 2005 
[156] 
Theonella 
swinhoei 
Lithistida 
Plytheonamide  
A, B 
Polypeptide 
Showed cytotoxicity against P388 murine 
leukemia cells with IC50 values of 78 and  
68 pg/mL, respectively. Linear polypeptides 
with unprecedented structural features 
Hachijo-jima Island, 
Japan, 2005 
[157] 
Neopetrosia sp. Haplosclerida 
Neopetrosiamide  
A, B 
Peptide (diastereomeric 
tricyclic) 
Active in inhibiting the amoeboid invasion  
by human tumor cells 
Near Milne Bay, Papua 
New Guinea, 2005 
[158] 
Prianos osiros Haplosclerida 
(3R,3′R,5S)-3,3′,5,19′-
tetrahydroxy-7′,8′-
didehydro-γ,ε-carotene-
8-one 
Acetylenic carotenoid Contains an unusual cytotoxic carotenoid 
Pohnpei,  
Micronesia, 2005 
[159] 
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Table 3. Cont. 
Ircinia sp. Dictyoceratida 
Irciniasulfonic  
acid B 
Fatty acid derivative 
(taurine conjugated) 
Reversed the multi-drug resistance to 
vincristine in KB/VJ300 cells at the 
concentration of 100 μM 
Tsuzumi Island, 
Fukuoka Prefecture, 
Japan, 2006 
[160] 
Suberites 
japonicus 
Hadromerida Seragamide A–F 
Depsipeptide  
(actin targeting) 
Caused multinuclei formation in cells at  
0.01–0.02 μg/mL 
Seragaki, Okinawa, 
Japan, 2006 
[161] 
Theonella 
swinhoei 
Lithistida Hurghadolide A Macrolide 
Caused disruption of the actin cytoskeleton  
at concentrations of 7.3 nM. Active against 
Candida albicans (MIC 31.3 μg/mL) 
Red Sea, Egypt, 2006 [89] 
Theonella 
swinhoei 
Lithistida Swinholide I Macrolide as above Red Sea, Egypt, 2006 [89] 
Coelocarteria cfr. 
singaporensis 
Poecilosclerida 
Coelodiol and Coelic 
acid 
Diterpene  
(ent-isocopalane) 
Inhibit the in vitro growth of MKN-45 cell 
line (human gastric adenocarcinoma) at  
20 and 40 μg/mL respectively 
Bunaken, Marine Park 
(North Sulawesi), 
Indonesia, 2006 
[162] 
Lendenfeldia sp. Dictyoceratida 
(S)-2,2′-Dimethoxy-1, 
1′-binaphthyl-5,5′,6,6′-
tetraol 
Naphthalene dimer 
Signiﬁcantly inhibited both hypoxia-induced 
(IC50 values 4.3 µM) and iron chelator (1,  
10-phenanthroline)-induced HIF-1 activation 
in T47D breast tumor cells. This compound 
inhibited HIF-1 activation at concentrations 
that were signiﬁcantly lower than those that 
suppressed tumor cell viability 
Collected at 2 m depth 
on May 22, 1993 
(sample C011337), from 
a sea grass bed, 
Indonesia, 2007 
[163] 
Erylus formosus Astrophorida Eryloside F1–F4 Triterpene glycoside 
At a concentration of 100 μg/mL were  
found to activate Ca2 influx into mouse 
spleenocytes. biosides having aglycons 
related to penasterol with additional 
oxidation patterns in their side chains 
Puerto Morelos (the 
Caribbean Sea), Mexico 
2007 
[164] 
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Table 3. Cont. 
Erylus formosus Astrophorida Eryloside M–Q Triterpene glycoside 
As above, contain new variants of 
carbohydrate chains with three, four and  
six sugar units. Contain 14-carboxy-24-
methylenelanost-8(9)-en-3β-ol 
Puerto Morelos  
(the Caribbean Sea), 
Mexico, 2007 
[164] 
Cacospongia 
mycofijiensis 
Dictyoceratida CTP-431 Thiopyrone 
Showed only mild cytotoxicity (IC50: 18 μM) 
against human colon carcinoma HCT-116. 
This compound has no previous precedent in 
natural products chemistry. Its structure 
including absolute configuration as 
8R,9R,10S,13S 
Beqa Lagoon, Fiji, 2008 [165] 
Homophymia sp. Lithistida Homophymine A Cyclodepsipeptide 
Exhibited cytoprotective activity against 
HIV-1 infection with a IC50 of 75 nM 
Coast of New 
Caledonia, 2008 
[166] 
Ianthella sp. Verongida 
Petrosterol-3,6-dione 
and 5α,6α-epoxy-
petrosterol 
C29 sterol 
Showed growth-inhibitory effects with IC50 
values of 8.4, 19.9, 17.8, 16.2 and 22.1 μM 
against lung (A549), colon (HT-29), breast 
(MCF-7), ovary (SK-OV-3), and two types  
of leukemia (HL-60 and U937) human  
cancer cell lines 
Namyet Island,  
Khanh Hoa province, 
Vietnam, 2009 
[167] 
Topsentia sp. Halichondrida 
Geodisterol-3-O-sulﬁte 
and 29-
demethylgeodisterol-3-
O-sulﬁte 
Sterol (sulphated) 
Reverses efﬂux pump mediated ﬂuconazole 
resistance. Also enhances ﬂuconazole activity 
in a Saccharomyces cerevisiae strain 
overexpressing the Candida albicans  
efﬂux pump MDR1, as well as in a 
ﬂuconazole-resistant Candida albicans 
clinical isolate known to overexpress MDR1 
Chuuk,  
Micronesia, 2009 
[168] 
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Table 3. Cont. 
Spongia 
(Heterofibria) sp. 
Dictyoceratida 
Heterofibrin A1–A3 
and B1–B3 
Fatty acid 
Possess a diyne-ene moiety, while the 
monolactyl and dilactyl moiety featured in 
selected heterofibrins is unprecedented in the 
natural products literature. Inhibited lipid 
droplet formation in A431 fibroblast cells  
(up to 60% at 10 μM) 
Great Australian Bight, 
Australia, 2010 
[169] 
Xestospongia sp. Haplosclerida Xestosaprol F–M 
Xestosaprol (pentacyclic 
compound) 
Showed moderate inhibition of the aspartic 
protease BACE1 (memapsin-2), which has a 
central role in the etiology of Alzheimer’s 
disease with the IC50 value of 135 ± 11 μM. 
First examples of a monooxygenated A-ring 
Coral reef at Sangalaki, 
Indonesia, 2010 
[170] 
Theonella 
swinhoei 
Lithistida Paltolides A–C 
Peptides 
(Anabaenopeptin like) 
Closely related to a group of anabaenopeptins 
that are submicromolar inhibitors of 
carboxypeptidase U with greater than 50 fold 
selectivity over other carboxypeptidases 
Uchelbeluu Reef,  
Palau, 2010 
[171] 
Neopetrosia 
proxima 
Haplosclerida Neopetrosiamine A 
Alkaloid (tetracyclic  
bis-piperidine) 
Exhibited strong inhibitory activity against 
MALME-3M melanoma cancer, CCRF-CEM 
leukemia, and MCF7 breast cancer with IC50 
values of 1.5, 2.0, and 3.5 μM, respectively. 
In vitro activity vs. pathogenic strain of 
Mycobacterium tuberculosis (H37Rv) and 
Plasmodium falciparum 
Mona Island,  
Puerto Rico, 2010 
[172] 
Iotrochota 
baculifera 
Poecilosclerida Baculiferins A–O 
O-sulfated pyrrole 
alkaloids 
Baculiferins C, E–H, and K–N (4, 6–9,  
12–15) are potent inhibitors of HIV-1 IIIB 
virus in both MT4 and MAGI cells. 
Additionally could bind to the HIV-1  
target proteins Vif, APOBEC3G, and gp41 
Inner coral reef,  
Hainan Island,  
China, 2010 
[173] 
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2.8. Distribution of New Compounds Based on Country/Geographical Area 
One important aspect of sponges is their geographical location. A high percentage of bioactive 
sponge species were reported from different geographical regions [174–176]. 
Figure 8 shows that the new compounds were mainly isolated from sponges collected from  
61 countries. Of these, sponges from Japan had the highest number of compounds (332) followed  
by Indonesia (235), Korea (211). Sponge samples from Australia and China contributed 187 and  
146 compounds, respectively, during the last decade. The Bahamas, Mexico, Palau, Papua New 
Guinea, Philippines and Vanuatu are the other countries which were the source of more than 50 new 
compounds found in the last ten years. The obvious question is why do some regions show a high diversity 
of compounds as well as an abundance of sponges? Studies showed that the highest concentration of 
toxic or antioxidant sponge metabolites are found in habitats such as coral reefs that are characterized 
by intense competition and feeding pressure from carnivorous fish [177]. The adaptive significance of 
the chemical defenses of sponges are that they are highly effective against most species of fish and  
a group of shell-less gastropods, the nudibranchs that feed on sponges and sequester their chemical 
armory [177]. An excellent paper on the global diversity of sponges includes global sponge diversity 
information which was collected from different regional projects and resources and also reviewed was 
information on invasive sponges that might well have some influence on distribution patterns in the 
future [83]. 
Figure 8. Total number of new compounds isolated from different marine sponges and 
their source locations from 2001 to 2010. 
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Figure 9 shows the total number of new compounds isolated from the top ten countries. It has been 
found that each year from 2001 to 2010 at least 20 new compounds were isolated from Japanese 
sponge samples, with the highest output occurring in 2004 and 2005 with 46 new compounds (Figure S2, 
Supplementary Information). From 2006 to 2009 at least 20 compounds were found each year in 
Indonesia. Marine invertebrates, which are plentiful in the Indo-Pacific regions including 
Indonesia, are rich in secondary metabolites and are becoming targets for the continuing search 
for bioactive compounds [178]. 
Figure 9. Total number of new compounds isolated from marine sponges from the top  
10 source countries from 2001 to 2010. 
 
Although in 2001 the highest contributors of new compounds derived from sponges were from 
Japan, Korea and Australia at 22.9%, 18.9% and 14.3%, respectively, the scenario changed during 
2010 where the highest contributions of new compounds came from China, Australia and Indonesia at 
23.9%, 21.3%, and 21%, respectively [179]. China started its marine high-tech program since 1996, 
and after 15 years it emerged as one of the highest contributors to marine sponge natural products 
discovery in 2010. This achievement demonstrates how significant the government science and 
technology funding policy can impact the development of marine biotechnology. Australia is one of 
only 17 recognised megabiodiverse countries primarily based on its highly biodiverse and endemic 
terrestrial flora and fauna [180,181]. While the full extent of Australian marine biodiversity remains 
relatively unexplored [182], several marine biodiversity hotspots including centers of endemicity have 
been recognized, especially in coral reefs [183,184], the temperate coastline [185] and the Great 
Australian Bight off the coast of South Australia [186]. There have been reports on the high species 
diversity of sponges in the north west [187–190], in the deep sea off the south west [191,192] of the 
Bight, and the Great Barrier Reef [189]. Therefore, there is urgent need to explore those potential 
locations in order to obtain new compounds and drugs for the future. 
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The Australian Institute of Marine Science (AIMS) conducted a study based on the Australian 
marine habitat and identified biogeographic bioactivity hotspots that correlated with biodiversity 
hotspots. AIMS found that high-level phylogeny, and therefore the metabolic machinery available to 
an organism, is a major basis of bioactivity, while habitat diversity and ecological circumstance are 
possible drivers in the stimulation of this machinery and bioactive secondary metabolism [193]. 
Therefore, in near future, knowledge of metabolomics coupled with genomics tool and bioinformatics 
could be a high level device for the exploration of target specific bioactive compounds from sponges. 
In addition, microbes associated with marine sponges could vary with the geographical area, so,  
if these associated bacteria are responsible for producing compounds, then it is possible that  
the same sponge species in different geographical locations could produce different secondary  
metabolites [194,195]. However, a recent study showed the stability of bacterial communities in  
two temperate sponges exposed to environmental variation, which is consistent with previous research 
on other temperate sponges. This study used next generation sequencing and revealed how different 
components of bacterial communities associated with Ecionemia alata and Tethya bergquistae 
responded to environmental variation in situ [196]. The similarity observed in bacterial communities 
among specimens occupying different habitats suggests that environmental variation occurring in those 
habitats does not affect the stability of the community, and hence, most likely does not radically alter 
the metabolism of these sponges. The study recommends further study to improve the understanding of 
the role of microbial symbiont communities which may affect the physiology and ecology of sponges 
on temperate rocky reefs [196]. 
A recent pyrosequencing analysis of 32 sponge species from eight locations around the world 
identified few bacterial species that are common to more than a handful of sponge species [177]. They 
stated that different sponges were found to contain different bacterial species (species-specific 
community) but share only very few bacterial species (core community) [197]. However, the bacterial 
species in different sponges are still more closely related to each other than, for example, to seawater 
bacteria (indicated by Plus-OTUs and sponge-specific clusters), consistent with previous studies 
suggesting at least partially overlapping communities among different sponges. Sponges therefore 
contain a uniform, sponge-specific bacterial community although each sponge species contains different 
bacterial species [197]. Perhaps, this is one of the main reasons for getting new compounds in species 
level regardless of the genera and order. Although we commented on this, based on our study of 
sponges of the last decade, further study to prove this hypothesis would be worthwhile. 
3. Conclusions 
In the decade 2001–2010 marine sponges continued to be the most promising source of marine 
natural products. Marine microorganisms and phytoplankton grew rapidly to become the third largest 
source by increasing their contribution from 9% to 39% during the decade. Sponges are a reservoir of 
marine microorganisms with up to 40%–60% as microbial biomass. In the coming decade sponge 
associated microorganisms promise to be an outstanding source of the NMNP. 
From the current trend of discovery it could be predicted that China, Australia and Indonesia will be 
the source of more new compounds in the future competing with Japan and Korea. However, although 
Indonesia is an excellent source of sponges, most of their studies were conducted by scientists in other 
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countries. Certainly, exploration of new compounds from marine sponges is dependent on government 
funding and policy, industrial interest and investment, research facilities, the expertise of scientists, 
infrastructure and laboratory facilities, equipment, machinery and institutional support. 
Astrophorida, Dictyoceratida, Halichondrida, Haplosclerida and Poecilosclerida were the key orders 
of sponges studied during the first decade of the 21st century. The examination of the contribution 
from an individual species revealed that regardless of the order each species contributed on average  
3–5 compounds. The high number of new compounds was the result of the high diversity of species 
from these particular orders. Alkaloids (20%), terpenes (14.7%) or terpenoids (8.3%) and peptides 
(6.8%) represented the three main chemical classes of compounds discovered from sponges in this 
period, and together with the other chemical classes showed a range of biological activities. Of all the 
biological activities investigated cytotoxicity or anticancer activity against different cancer cell lines 
was most frequently reported at 53.6%. Antibacterial and antifungal activity were two other areas 
where new compounds showed potential activity at 9.4% and 7.2%, respectively. Anti-Alzheimer’s, 
antibacterial, antituberculosis, anticancer, antifungal, anti-inflammatory, antimalarial, antiviral, anti-HIV 
were the other activities exhibited by the new compounds from sponges. Because sponge extracts 
showed potent cytotoxic activity, which is often reported as anticancer activity, it is very important  
to study the mode of action of these extracts by isolating pure compounds rather than only  
testing cytotoxicity. 
The order Dictyoceratida was found to be the most prolific producer of new compounds among  
all the sponge orders studied. Dysidea sp. and Ircinia sp. were found to be the most promising genera 
because of their capacity for producing new bioactive compounds. 
In any event, the discovery of marine natural products from sponges relies particularly on finding 
new genera and species from the most prolific to the least abundant orders, which is still achievable.  
In order to overcome the problem of production of sponge-derived compounds, synthesis of bioactive, 
low molecular weight compounds by cloning biosynthetic gene clusters using recombinant techniques 
could be applied. Most importantly, sponge derived compounds should be utilized with a combination 
of innovative technologies which could develop new fields of application that will impact significantly 
on biotechnology. 
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